• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在对照和未知人群中进行的 SARS-CoV-2 血清学检测表明病毒中和检测的必要性。

SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing.

机构信息

Department of Immunology, Center for Innate Immunity and Immune Disease, University of Washington, Seattle, Washington, USA.

Department of Pediatric Infectious Disease, Seattle Children's Hospital/University of Washington, Seattle, Washington, USA.

出版信息

J Infect Dis. 2021 Apr 8;223(7):1120-1131. doi: 10.1093/infdis/jiaa797.

DOI:10.1093/infdis/jiaa797
PMID:33367830
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7798987/
Abstract

BACKGROUND

To determine how serologic antibody testing outcome links with virus neutralization of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we evaluated individuals for SARS-CoV-2 antibody level and viral neutralization.

METHODS

We compared serum Ig levels across platforms of viral antigens and antibodies with 15 positive and 30 negative SARS-CoV-2 controls followed by viral neutralization assessment. We then applied these platforms to a clinically relevant cohort of 114 individuals with unknown histories of SARS-CoV-2 infection.

RESULTS

In controls, the best-performing virus-specific antibody detection platforms were SARS-CoV-2 receptor binding domain (RBD) IgG (sensitivity 87%, specificity 100%, positive predictive value [PPV] 100%, negative predictive value [NPV] 94%), spike IgG3 (sensitivity 93%, specificity 97%, PPV 93%, NPV 97%), and nucleocapsid protein (NP) IgG (sensitivity 93%, specificity 97%, PPV 93%, NPV 97%). Neutralization of positive and negative control sera showed 100% agreement. Twenty individuals with unknown history had detectable SARS-CoV-2 antibodies with 16 demonstrating virus neutralization. Spike IgG3 provided the highest accuracy for predicting serologically positive individuals with virus neutralization activity (misidentified 1/20 unknowns compared to 2/20 for RBD and NP IgG).

CONCLUSIONS

The coupling of virus neutralization analysis to a spike IgG3 antibody test is optimal to categorize patients for correlates of SARS-CoV-2 immune protection status.

摘要

背景

为了确定血清抗体检测结果与严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的病毒中和作用之间的关系，我们评估了个体的 SARS-CoV-2 抗体水平和病毒中和作用。

方法

我们比较了针对病毒抗原和抗体的不同平台的血清 Ig 水平，包括 15 名阳性和 30 名阴性 SARS-CoV-2 对照者，然后进行了病毒中和评估。然后，我们将这些平台应用于一个具有 114 名未知 SARS-CoV-2 感染史的临床相关队列。

结果

在对照组中，表现最佳的病毒特异性抗体检测平台是 SARS-CoV-2 受体结合域（RBD）IgG（敏感性 87%，特异性 100%，阳性预测值 [PPV] 100%，阴性预测值 [NPV] 94%）、刺突 IgG3（敏感性 93%，特异性 97%，PPV 93%，NPV 97%）和核衣壳蛋白（NP）IgG（敏感性 93%，特异性 97%，PPV 93%，NPV 97%）。阳性和阴性对照血清的中和作用显示出 100%的一致性。20 名具有未知病史的个体具有可检测到的 SARS-CoV-2 抗体，其中 16 名具有病毒中和作用。刺突 IgG3 对预测具有病毒中和活性的血清学阳性个体具有最高的准确性（与 RBD 和 NP IgG 相比，错误识别了 1/20 个未知个体，而不是 2/20 个）。

结论

将病毒中和分析与刺突 IgG3 抗体测试相结合，是分类 SARS-CoV-2 免疫保护状态相关因素的最佳方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df1/8030719/3fcd55c01765/jiaa797f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df1/8030719/6bcd9196ae2f/jiaa797f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df1/8030719/5f342ec2f600/jiaa797f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df1/8030719/aa383a3db071/jiaa797f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df1/8030719/4504d5c7df80/jiaa797f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df1/8030719/58a4f3b4bb03/jiaa797f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df1/8030719/3fcd55c01765/jiaa797f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df1/8030719/6bcd9196ae2f/jiaa797f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df1/8030719/5f342ec2f600/jiaa797f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df1/8030719/aa383a3db071/jiaa797f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df1/8030719/4504d5c7df80/jiaa797f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df1/8030719/58a4f3b4bb03/jiaa797f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4df1/8030719/3fcd55c01765/jiaa797f0006.jpg

相似文献

1
SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing.在对照和未知人群中进行的 SARS-CoV-2 血清学检测表明病毒中和检测的必要性。
J Infect Dis. 2021 Apr 8;223(7):1120-1131. doi: 10.1093/infdis/jiaa797.
2
Anti-SARS-CoV-2 total immunoglobulin and neutralising antibody responses in healthy blood donors throughout the COVID-19 pandemic: a longitudinal observational study.在整个 COVID-19 大流行期间健康献血者的抗 SARS-CoV-2 总免疫球蛋白和中和抗体反应：一项纵向观察研究。
Swiss Med Wkly. 2024 Jul 1;154:3408. doi: 10.57187/s.3408.
3
Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein.SARS-CoV-2 感染个体在针对刺突糖蛋白的抗体反应的域特异性和相对效力方面存在有限的变异性。
Microbiol Spectr. 2022 Feb 23;10(1):e0267621. doi: 10.1128/spectrum.02676-21. Epub 2022 Jan 26.
4
Development and Validation of Novel Cell-free Direct Neutralization Assay for SARS-CoV-2.新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）无细胞直接中和试验的开发与验证
J Virol Methods. 2025 Dec;338:115201. doi: 10.1016/j.jviromet.2025.115201. Epub 2025 Jun 9.
5
Individuals Infected with SARS-CoV-2 Prior to COVID-19 Vaccination Maintain Vaccine-Induced RBD-Specific Antibody Levels and Viral Neutralization Activity for One Year.在接种新冠疫苗之前感染过新冠病毒的个体，其疫苗诱导的RBD特异性抗体水平和病毒中和活性可维持一年。
Viruses. 2025 Apr 29;17(5):640. doi: 10.3390/v17050640.
6
Detection of SARS-CoV-2- specific antibodies in domestic cats using different ELISA tests.使用不同的酶联免疫吸附测定法检测家猫体内的新冠病毒特异性抗体。
J Virol Methods. 2025 Apr;333:115099. doi: 10.1016/j.jviromet.2024.115099. Epub 2024 Dec 9.
7
Antibody Levels From High-Throughput Variant-Specific SARS-CoV-2 Anti-Spike Immunoglobulin G and Angiotensin-Converting Enzyme 2 Neutralization Assays Correlate With COVID-19 Infection Risk in a Large Population.高通量变异株特异性SARS-CoV-2抗刺突免疫球蛋白G和血管紧张素转换酶2中和试验检测的抗体水平与大量人群的COVID-19感染风险相关。
J Infect Dis. 2025 Apr 15;231(4):921-930. doi: 10.1093/infdis/jiae622.
8
Antibody tests for identification of current and past infection with SARS-CoV-2.抗体检测用于鉴定 SARS-CoV-2 的现症感染和既往感染。
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2.
9
Establishment of human post-vaccination SARS-CoV-2 standard reference sera.建立人接种 SARS-CoV-2 疫苗后标准参考血清。
J Immunol Methods. 2024 Jul;530:113698. doi: 10.1016/j.jim.2024.113698. Epub 2024 May 31.
10
SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus.SARS-CoV-2 特异性抗体和中和测定法揭示了针对该病毒的广泛体液免疫反应。
Commun Biol. 2021 Jan 29;4(1):129. doi: 10.1038/s42003-021-01649-6.

引用本文的文献

1
Comparison of six COVID-19 serology assays for detection of antibodies from patients infected with ancestral and a spectrum of SARS-CoV-2 variants.六种用于检测感染原始毒株和一系列新冠病毒变异株患者抗体的新冠病毒血清学检测方法的比较
Access Microbiol. 2025 Jul 7;7(7). doi: 10.1099/acmi.0.000974.v3. eCollection 2025.
2
Dynamics of SARS-CoV-2 VOC Neutralization and Novel mAb Reveal Protection against Omicron.SARS-CoV-2 VOC 中和动力学和新型单抗揭示了对奥密克戎的保护作用。
Viruses. 2023 Feb 14;15(2):530. doi: 10.3390/v15020530.
3
Comprehensive assessment of SARS-CoV-2 antibodies against various antigenic epitopes after naive COVID-19 infection and vaccination (BNT162b2 or ChAdOx1 nCoV-19).

本文引用的文献

1
Predictors of severe symptomatic laboratory-confirmed SARS-CoV-2 reinfection.预测严重有症状的实验室确诊 SARS-CoV-2 再感染的因素。
Public Health. 2021 Apr;193:113-115. doi: 10.1016/j.puhe.2021.01.021. Epub 2021 Feb 12.
2
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.SARS-CoV-2 mRNA-1273疫苗接种后反应的持久性。
N Engl J Med. 2021 Jan 7;384(1):80-82. doi: 10.1056/NEJMc2032195. Epub 2020 Dec 3.
3
Genomic evidence for reinfection with SARS-CoV-2: a case study.基因组证据表明 SARS-CoV-2 再次感染：一项案例研究。
新型冠状病毒感染和接种（BNT162b2 或 ChAdOx1 nCoV-19）后针对各种抗原表位的 SARS-CoV-2 抗体的综合评估。
Front Immunol. 2022 Dec 12;13:1038712. doi: 10.3389/fimmu.2022.1038712. eCollection 2022.
4
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.二价 SARS-CoV-2 mRNA 疫苗提高中和广度并预防小鼠感染奥密克戎变异株 BA.5。
Nat Med. 2023 Jan;29(1):247-257. doi: 10.1038/s41591-022-02092-8. Epub 2022 Oct 20.
5
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant.二价新冠病毒mRNA疫苗可增加中和广度并预防BA.5奥密克戎变种。
bioRxiv. 2022 Sep 13:2022.09.12.507614. doi: 10.1101/2022.09.12.507614.
6
Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice.变异匹配或历史 mRNA 疫苗加强接种可预防奥密克戎感染小鼠。
Cell. 2022 Apr 28;185(9):1572-1587.e11. doi: 10.1016/j.cell.2022.03.037. Epub 2022 Mar 28.
7
Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice.使用与奥密克戎匹配的或历史上的mRNA疫苗进行加强免疫可增强中和抗体反应，并保护小鼠免受B.1.1.529感染。
bioRxiv. 2022 Feb 9:2022.02.07.479419. doi: 10.1101/2022.02.07.479419.
8
Performance of anterior nares and tongue swabs for nucleic acid, Nucleocapsid, and Spike antigen testing for detecting SARS-CoV-2 against nasopharyngeal PCR and viral culture.前鼻拭子和咽拭子在核酸、核衣壳和刺突抗原检测中的性能，以检测 SARS-CoV-2 与鼻咽 PCR 和病毒培养相比。
Int J Infect Dis. 2022 Apr;117:287-294. doi: 10.1016/j.ijid.2022.02.009. Epub 2022 Feb 9.
9
T cell response to intact SARS-CoV-2 includes coronavirus cross-reactive and variant-specific components.T细胞对完整的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的反应包括冠状病毒交叉反应性成分和变体特异性成分。
JCI Insight. 2022 Mar 22;7(6):e158126. doi: 10.1172/jci.insight.158126.
10
SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters.新冠病毒奥密克戎变异株在小鼠和仓鼠中引起轻症疾病。
Nature. 2022 Mar;603(7902):687-692. doi: 10.1038/s41586-022-04441-6. Epub 2022 Jan 21.
Lancet Infect Dis. 2021 Jan;21(1):52-58. doi: 10.1016/S1473-3099(20)30764-7. Epub 2020 Oct 12.
4
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.《 老年人中新型冠状病毒 mRNA-1273 疫苗的安全性和免疫原性》
N Engl J Med. 2020 Dec 17;383(25):2427-2438. doi: 10.1056/NEJMoa2028436. Epub 2020 Sep 29.
5
Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak.血清学鉴定在西雅图最初暴发期间就诊于医院的儿童中的 SARS-CoV-2 感染。
Nat Commun. 2020 Sep 1;11(1):4378. doi: 10.1038/s41467-020-18178-1.
6
Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing.2019 年冠状病毒病（COVID-19）通过全基因组测序确认为与严重急性呼吸综合征冠状病毒 2 株系不同的病毒再次感染。
Clin Infect Dis. 2021 Nov 2;73(9):e2946-e2951. doi: 10.1093/cid/ciaa1275.
7
Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients.新冠病毒肺炎患者中中和抗体反应的快速产生
Cell Rep Med. 2020 Jun 23;1(3):100040. doi: 10.1016/j.xcrm.2020.100040. Epub 2020 Jun 8.
8
A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation.一种高通量中和抗体检测方法用于 COVID-19 的诊断和疫苗评估。
Nat Commun. 2020 Aug 13;11(1):4059. doi: 10.1038/s41467-020-17892-0.
9
A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction.一种基于抗体介导的 ACE2-刺突蛋白-蛋白相互作用阻断的 SARS-CoV-2 假病毒中和试验。
Nat Biotechnol. 2020 Sep;38(9):1073-1078. doi: 10.1038/s41587-020-0631-z. Epub 2020 Jul 23.
10
Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020.2020年3月23日至5月12日美国10个地点针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抗体的血清流行率
JAMA Intern Med. 2020 Jul 21. doi: 10.1001/jamainternmed.2020.4130.